Every 10-Q that Emerson Electric Co. (EMR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EMR filings page.
Emerson Electric reported solid third-quarter fiscal 2026 results, with net sales of $4.87 billion, up 7% year over year, and gross margin expanding to 54.5% helped by $82 million of tariff refunds. Earnings from continuing operations attributable to common shareholders rose 24% to $718 million, and diluted EPS from continuing operations increased to $1.28. Adjusted diluted EPS was $1.71, up 13%, driven mainly by higher volume, pricing and lower acquisition-related costs, partly offset by higher restructuring expense.
Software & Systems sales grew 11% and Intelligent Devices 6%, both delivering higher earnings, while Safety & Productivity sales grew 3% but saw lower reported margins due to increased restructuring. For the first nine months, revenue reached $13.78 billion, up 5%, and diluted EPS from continuing operations was $3.45, up 19%; adjusted diluted EPS was $4.71, up 8%.
Operating cash flow from continuing operations for the first nine months was $2.90 billion and free cash flow $2.62 billion, supporting $0.90 billion of share repurchases and $0.94 billion of dividends. Emerson ended June 30 2026 with $42.21 billion in total assets, $20.39 billion of equity, a backlog of about $9.6 billion, and expects fiscal 2026 adjusted diluted EPS of approximately $6.55.
Emerson Electric Co. reported modest growth for the quarter and first half ended March 31, 2026. Second‑quarter net sales were $4.56 billion, up 3%, with underlying sales up 0.5% as higher pricing offset lower volumes and headwinds from software renewal timing and Middle East conflict.
Net earnings attributable to common stockholders rose to $618 million from $485 million, and diluted EPS increased to $1.10 from $0.86, largely due to lower acquisition and transaction costs versus the prior year. On an adjusted basis, diluted EPS was $1.54, up 4% from $1.48. Segment sales grew 4% in Software & Systems, 2% in Intelligent Devices, and 5% in Safety & Productivity.
For the first six months, net sales were $8.91 billion, up 3%, with diluted EPS of $2.17 versus $1.88 and adjusted EPS of $3.00 versus $2.86. Operating cash flow from continuing operations was $1.48 billion, below last year as working capital increased, while free cash flow was $1.30 billion. Emerson guides fiscal 2026 net sales up about 4.5%, diluted EPS of $4.79–$4.89, and adjusted diluted EPS of $6.45–$6.55, and expects $3.5–$3.6 billion of free cash flow.
Emerson Electric reported fiscal Q1 2026 net sales of $4.35 billion, up 4%, with underlying sales up 2% and a 2% tailwind from foreign exchange. Net earnings attributable to common stockholders rose to $605 million and diluted EPS increased 5% to $1.07.
Adjusted diluted EPS was $1.46, up 6%, as higher pricing and cost savings offset softer volumes and the timing of software renewals. Software & Systems grew sales 5% and earnings 26%, Intelligent Devices grew sales 4%, and Safety & Productivity grew sales 3%.
Operating cash flow was $699 million and free cash flow $602 million. Emerson returned cash through $250 million of share repurchases and dividends, and guided fiscal 2026 sales up about 5.5%, GAAP EPS of $4.78–$4.93 and adjusted EPS of $6.40–$6.55, with expected free cash flow of $3.5–$3.6 billion.
Emerson Electric (EMR) Q3-25 10-Q highlights:
- Net sales rose 4% YoY to $4.55 bn; underlying growth +3% (price +2.5 ppts, volume +0.5 ppt).
- Diluted EPS from continuing ops surged 72% to $1.03, aided by the absence of last year’s $0.38 Copeland note loss; adjusted EPS up 6% to $1.52.
- Segment mix: Intelligent Devices sales +4% (margin 22.5%), Software & Control +3% (margin 16.7%); Test & Measurement loss narrowed sharply ($-26 m vs $-88 m).
- YTD (9 mo) sales +2% to $13.16 bn; diluted EPS $2.91 vs $1.84. Gross margin improved 260 bp to 53.2% on lower purchase-accounting amortization and pricing.
- AspenTech consolidation: on 12 Mar 25 EMR bought remaining AspenTech shares for ~$7.2 bn; AspenTech now in Control Systems & Software. Deal drove $7.2 bn equity reduction, $1.5 bn new long-term notes and $5.4 bn commercial paper.
- Balance sheet shifts: Cash fell to $2.2 bn (-$1.4 bn YTD); short-term borrowings jumped to $6.0 bn; net debt/EBITDA pro-forma ~2.6×. Equity down to $19.9 bn from $27.5 bn as NCI largely eliminated.
- Operating cash flow modestly lower at $2.09 bn (-7% YoY); capex $263 m; financing outflow $3.0 bn (buybacks, dividends, AspenTech purchase).
- Backlog stands at $8.9 bn; 75% expected to convert within 12 months.
- Effective tax rate Q3 21% (up 200 bp) and YTD 25% (up 500 bp) due to AspenTech-related discrete items.
Key takeaways: Emerson delivered solid topline and adjusted profit growth while integrating AspenTech, but leverage, lower cash and higher taxes temper the near-term outlook.